G · Genpact Limited · Stock research

Current Thesis

The leg on offer is a re-rate: a headcount-priced services company being repriced as a seller of the technology that was supposed to displace it. Q2 2026 (released 2026-08-06) made the split explicit — Advanced Technology Solutions $363M, +24.1% YoY, 27% of net revenue; Core Business Services $980M, +1.9% YoY, the other 73%. Management raised full-year ATS growth guidance to at least 25% (from mid-teens) while holding total net revenue growth at "at least 7%," because roughly two points of full-year revenue are being removed by exiting non-strategic work, concentrated in the second half. Shares closed $34.29 on 2026-08-07, 28.5% below the 52-week high of $47.99, after trading down about 3.2% intraday on the reaction session to a beat. The operating pivot is compounding; the multiple has not moved for it.

Bullish and bearish views on Genpact Limited

The model's bull view on Genpact Limited (G), in brief: ATS revenue $363M in Q2 2026, +24.1% YoY, and full-year ATS guidance lifted to at least 25% growth on the 2026-08-06 call — a guidance raise on the segment that carries the narrative. The bear view: The raise was cosmetic at the total-company line. Both cases follow in full.

Bull Case

• ATS revenue $363M in Q2 2026, +24.1% YoY, and full-year ATS guidance lifted to at least 25% growth on the 2026-08-06 call — a guidance raise on the segment that carries the narrative.
• Agentic solutions on track to book over $1B of total contract value in 2026, described on the Q2 call as roughly five times the 2025 figure; agentic work was close to 40% of Q2 bookings and more than half of cumulative awarded contract value came from new clients.
• Large-deal count 12 year-to-date versus 6 in the prior-year period, with 6 signed in Q2 against 3 a year earlier (Q2 call, 2026-08-06).
• Non-FTE revenue passed 50% of total for the first time. That decouples the revenue line from billable headcount, which is the structural answer to the argument that agents deflate seat-based services.
• Gross margin 36.5% in Q2, up roughly 60bps YoY and the thirteenth consecutive quarter of expansion; full-year guidance is ~36.5% gross and ~17.7% adjusted operating margin, up ~25bps.
• Adjusted EPS $1.00, +13.6% YoY on 7.1% revenue growth — operating leverage, not a buyback artifact alone. ~1.6M shares repurchased for ~$50M in Q2 plus $32M of dividends.
• A $34.29 close against full-year adjusted EPS guidance of more than $4.09 is a low multiple relative to the services complex; the quarterly dividend was raised to $0.1875 on 2026-07-16.

Bear Case

• The raise was cosmetic at the total-company line. FY2026 adjusted EPS guided to "more than $4.09" against a $4.07 consensus and revenue "more than $5.436B" against $5.435B — inside the rounding.
• Q3 guidance sits at or under consensus on every line: revenue $1.369–1.382B vs $1.382B, adjusted EPS $1.04–1.05 vs $1.05, GAAP EPS $0.89–0.90 vs $0.91.
• Core Business Services grew 1.9% in Q2 and was guided flat-to-slightly-down for Q3. Seventy-three percent of the book at zero growth caps what a 27% segment growing 25% can do to the consolidated line.
• The market sold the print. Shares fell roughly 3% on 2026-08-07 even as four of five brokers moved targets higher the same day.
• Cash conversion is back-half dependent: six-month operating cash flow of $48.9M against $50M of Q2 repurchases and $32M of Q2 dividends. Cash $517.4M versus total debt $1.18B at 2026-06-30.
• If clients capture the AI savings through price, the growth shows up as flat revenue and compressed margin. Thirteen quarters of gross-margin expansion is the counter-evidence so far; one reversal ends it.

Setup & Price Structure

• Basis: close $34.29 on 2026-08-07; 52-week high $47.99 (-28.5%); three-month return +5.9%; RSI(14) 64.3.
• The 2026-08-07 session was the reaction to the 2026-08-06 release. Third-party coverage put the intraday move at about -3.2% to roughly $35. A pre-print advance was sold into a beat, which is why RSI reads elevated on a stock nearly 30% below its high.
• Published targets after the print, all dated 2026-08-07: Citigroup Neutral $36, Susquehanna Neutral $37, TD Cowen Buy $43 (raised from $42), JPMorgan Neutral $45, Needham Buy $45 (lowered). Every target sits above the close; three of the five ratings are Neutral, so the target migration is not a ratings cycle.
• Crowding observables: no earnings date inside 30 days; the issuer is a net buyer of its own stock (~1.6M shares/~$50M in Q2) rather than an issuer into strength; no insider Form 4 activity in the current window; coverage is sell-side and institutional, with no retail-sentiment clustering visible in the news flow. Sentiment is not the constraint here — willingness to pay a higher multiple is.
• Life-cycle: MATURING. The agentic-operations framework has been the stated strategy since the June 2025 strategy day and ATS has been a reported line for several quarters, so this is not fresh attention. It still works in the numbers — ATS +24.1%, thirteen quarters of margin expansion — while flow moderates: a beat plus a segment guidance raise produced a down day on 2026-08-07. Two more prints of ≥25% ATS growth with no multiple response would move the label toward DEAD.

Catalyst Calendar (next 30 days)

• ~2026-08-12 (est.) — Q2 FY26 Form 10-Q. Carries headcount, receivables and remaining repurchase authorization that the earnings summary does not.
• 2026-09-10 — record date for the $0.1875/share Q3 dividend declared 2026-07-16 (payable 2026-09-24). The nearest hard corporate date; it resolves nothing about the thesis.
• ~2026-09-25 (est.) — Accenture fiscal Q4 results. Sector bookings read-through; Genpact's multiple has historically moved with the services complex rather than independently of it.
• ~2026-11-05 (est.) — Q3 FY26 print. The genuine binary: whether Core Business Services declines as guided, whether ATS holds ≥25%, and whether the ~2pp exit headwind lands as sized.

What Would Change Our Mind

The 73% is what breaks this. Core Business Services grew 1.9% to $980M in Q2 and was guided flat-to-slightly-down for Q3; management sized the full-year drag from exiting non-strategic work at roughly two points, concentrated in H2. If that segment prints an outright year-over-year decline at the Q3 report (~2026-11-05, est.) while ATS growth slips under 20%, the mix argument stops being a re-rate case and becomes a shrinking base with a fast-growing corner. A cut to the "at least 7%" full-year revenue growth frame would say the exits were larger than disclosed. On the tape, a weekly close below $32 erases the entire three-month advance and the shelf built around the Q2 release, leaving no structure between the price and the year's lows. In the other direction: sustained trade back through the $38–$40 area alongside a Q3 print with CBS stable and ATS at or above 25% would be the first evidence the market is paying for the pivot rather than discounting the legacy book.

Correlation Notes

• Moves with the IT and business-process services complex — Accenture, Cognizant, Infosys, Wipro, EPAM. Accenture's fiscal Q4 (~2026-09-25, est.) is the sector's next dated sentiment event and typically resets peer multiples before Genpact reports.
• Inverse in narrative to the AI-infrastructure trade: the premise that agents replace seats bids compute and compresses services multiples. Genpact's 28.5% drawdown from $47.99 is the visible form of that discount, and the ATS line is the direct rebuttal being tested each quarter.
• FX matters at the margin: Q2 reported growth 7.1% versus 6.9% constant currency (2026-08-06 release). The India-weighted delivery cost base makes INR/USD a margin input, not just a translation effect.
• Rate-sensitive on the balance sheet: $1.18B total debt against $517.4M cash at 2026-06-30, with capital returns running ahead of first-half operating cash flow.